TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Camurus AB ( (SE:CAMX) ) has provided an update.
Camurus has announced an increase in its number of shares and votes following the exercise of 24,200 employee stock options from its ESOP 2022/2026 program. This increase reflects the company’s ongoing commitment to employee participation and could potentially enhance its market positioning by aligning employee interests with corporate growth.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK691.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
More about Camurus AB
Camurus is an international biopharmaceutical company focused on developing and commercializing long-acting medicines for severe and chronic diseases. Utilizing its proprietary FluidCrystal technology, Camurus has a robust R&D pipeline targeting dependence, pain, cancer, and endocrine diseases. The company operates in Europe, the US, and Australia, with its headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm under the ticker CAMX.
Average Trading Volume: 100,559
Technical Sentiment Signal: Buy
Current Market Cap: SEK37.11B
For a thorough assessment of CAMX stock, go to TipRanks’ Stock Analysis page.